Arcus Biosciences, Inc.
RCUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $26,000 | $160,000 | $28,000 | $26,000 |
| % Growth | -83.8% | 471.4% | 7.7% | – |
| Cost of Goods Sold | $2,000 | $0 | $0 | $0 |
| Gross Profit | $24,000 | $160,000 | $28,000 | $26,000 |
| % Margin | 92.3% | 100% | 100% | 100% |
| R&D Expenses | $141,000 | $139,000 | $122,000 | $101,000 |
| G&A Expenses | $27,000 | $29,000 | $28,000 | $28,000 |
| SG&A Expenses | $27,000 | $29,000 | $28,000 | $28,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,000 | $0 | $0 | $0 |
| Operating Expenses | $166,000 | $168,000 | $150,000 | $129,000 |
| Operating Income | -$142,000 | -$8,000 | -$122,000 | -$103,000 |
| % Margin | -546.2% | -5% | -435.7% | -396.2% |
| Other Income/Exp. Net | $7,000 | $0 | $10,000 | $9,000 |
| Pre-Tax Income | -$135,000 | -$8,000 | -$112,000 | -$94,000 |
| Tax Expense | $0 | $0 | $0 | $1,000 |
| Net Income | -$135,000 | -$8,000 | -$112,000 | -$94,000 |
| % Margin | -519.2% | -5% | -400% | -361.5% |
| EPS | -1.27 | 0.043 | -1.14 | -1.03 |
| % Growth | -3,026.3% | 103.8% | -10.7% | – |
| EPS Diluted | -1.27 | 0.043 | -1.14 | -1.03 |
| Weighted Avg Shares Out | 106,500 | 106,100 | 98,400 | 91,700 |
| Weighted Avg Shares Out Dil | 106,500 | 106,500 | 98,400 | 91,700 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,000 | $10,000 | $11,000 | $12,000 |
| Interest Expense | $3,000 | $2,000 | $1,000 | $2,000 |
| Depreciation & Amortization | $2,000 | $2,000 | $3,000 | $3,000 |
| EBITDA | -$130,000 | $4,000 | -$108,000 | -$89,000 |
| % Margin | -500% | 2.5% | -385.7% | -342.3% |